Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DolACT: Dolutegravir Interactions with Antimalarials
NCT02242799Phase 1Completed
- Sponsor
- University of Liverpool
- Start
- Jun 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by University of Liverpool. Primary endpoints: Area Under the Curve, Maximum Concentration and 3 more. Started Jun 2015; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02242799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242799.